First evidence for continuous circulation of hepatitis A virus subgenotype IIA in Central Africa.


Journal

Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672

Informations de publication

Date de publication:
11 2020
Historique:
received: 03 01 2020
revised: 30 05 2020
accepted: 08 06 2020
pubmed: 22 6 2020
medline: 26 8 2021
entrez: 22 6 2020
Statut: ppublish

Résumé

Although a high seroprevalence of antibodies against hepatitis A virus (HAV) has been estimated in Central Africa, the current status of both HAV infections and seroprevalence of anti-HAV antibodies remains unclear due to a paucity of surveillance data available. We conducted a serological survey during 2015-2017 in Gabon, Central Africa, and confirmed a high seroprevalence of anti-HAV antibodies in all age groups. To identify the currently circulating HAV strains and to reveal the epidemiological and genetic characteristics of the virus, we conducted molecular surveillance in a total of 1007 patients presenting febrile illness. Through HAV detection and sequencing, we identified subgenotype IIA (HAV-IIA) infections in the country throughout the year. A significant prevalence trend emerged in the young child population, presenting several infection peaks which appeared to be unrelated to dry or rainy seasons. Whole-genome sequencing and phylogenetic analyses revealed local HAV-IIA evolutionary events in Central Africa, indicating the circulation of HAV-IIA strains of a region-specific lineage. Recombination analysis of complete genome sequences revealed potential recombination events in Gabonese HAV strains. Interestingly, Gabonese HAV-IIA possibly acquired the 5'-untranslated region (5'-UTR) of the rare subgenotype HAV-IIB in recent years, suggesting the present existence of HAV-IIB in Central Africa. These findings indicate a currently stable HAV-IIA circulation in Gabon, with a high risk of infections in children aged under 5 years. Our findings will enhance the understanding of the current status of HAV infections in Central Africa and provide new insight into the molecular epidemiology and evolution of HAV genotype II.

Identifiants

pubmed: 32564517
doi: 10.1111/jvh.13348
pmc: PMC7586949
doi:

Substances chimiques

Hepatitis A Antibodies 0

Banques de données

GENBANK
['MH577314', 'AY644676', 'K02990', 'X75215', 'M14707', 'M20273', 'AY644670', 'AB279732', 'AB279735', 'LC515196', 'LC515208', 'KC632110', 'KC632113', 'KC632115', 'LC515202']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1234-1242

Informations de copyright

© 2020 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.

Références

J Clin Virol. 2005 Feb;32(2):128-36
pubmed: 15653415
Virus Res. 2007 Jun;126(1-2):116-27
pubmed: 17376556
Int J Infect Dis. 2020 Feb;91:129-136
pubmed: 31821892
Int J Health Geogr. 2011 Oct 18;10:57
pubmed: 22008459
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):770-775
pubmed: 28074040
J Viral Hepat. 2020 Nov;27(11):1234-1242
pubmed: 32564517
Infect Genet Evol. 2014 Jan;21:227-43
pubmed: 24200587
J Hepatol. 2017 Sep 5;:
pubmed: 28887164
Virology. 2003 Jun 20;311(1):51-9
pubmed: 12832202
J Gen Virol. 2002 Jan;83(Pt 1):53-60
pubmed: 11752700
World J Hepatol. 2012 Mar 27;4(3):68-73
pubmed: 22489258
PLoS Biol. 2019 Apr 30;17(4):e3000229
pubmed: 31039149
Vaccine. 2010 Sep 24;28(41):6653-7
pubmed: 20723630
J Virol. 1992 Apr;66(4):2208-16
pubmed: 1312628
Virus Genes. 2010 Apr;40(2):222-4
pubmed: 20012679
J Med Virol. 2006 Aug;78(8):1015-24
pubmed: 16789007
mSphere. 2019 Jan 23;4(1):
pubmed: 30674646
EBioMedicine. 2019 Jan;39:348-357
pubmed: 30472089
Nat Protoc. 2017 Jun;12(6):1261-1276
pubmed: 28538739
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
J Med Virol. 2012 May;84(5):728-32
pubmed: 22431020
PLoS One. 2013 Nov 06;8(11):e74546
pubmed: 24223112
J Gen Virol. 2004 Oct;85(Pt 10):2943-2952
pubmed: 15448357
Appl Environ Microbiol. 2006 Jun;72(6):3846-55
pubmed: 16751488
J Clin Microbiol. 2010 Sep;48(9):3306-15
pubmed: 20592136
Virus Res. 2011 Jan;155(1):316-24
pubmed: 21056065

Auteurs

Haruka Abe (H)

Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.

Yuri Ushijima (Y)

Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.

Rodrigue Bikangui (R)

Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany.

Georgelin N Ondo (GN)

Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.

Vahid R Zadeh (VR)

Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.

Christelle M Pemba (CM)

Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.

Patrick I Mpingabo (PI)

Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.

Yui Igasaki (Y)

Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.

Sophia G de Vries (SG)

Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Division of Internal Medicine, Department of Infectious Diseases, Center of Tropical Medicine and Travel Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.

Martin P Grobusch (MP)

Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany.
Division of Internal Medicine, Department of Infectious Diseases, Center of Tropical Medicine and Travel Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.

Marguerite M Loembe (MM)

Université des Sciences de la Santé de Libreville, Libreville, Gabon.

Selidji T Agnandji (ST)

Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany.

Bertrand Lell (B)

Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.

Jiro Yasuda (J)

Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, Nagasaki, Japan.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH